(Updates share move, adds milestone, broker comment)
** Shares in Swiss medical device firm Medacta MOVE.S drop
19% at open, hitting their record low since the company's
listing in April
** The company cut its FY guidance on Thursday after weaker
than expected sales in the United States urn:newsml:reuters.com:*:nASN0000X7
** "The slip in guidance so soon after IPO (where the story
was for high growth, high profitability) is unlikely to sit well
with the market," JP Morgan says
** It points to the fact that at the time of the company's
listing, the U.S. business was to be a future growth driver
** "The magnitude of the shortfall (...) is worrying,"
Credit Suisse says, adding that it points to rapidly slowing
growth
** The broker sees the profit warning putting Medacta's
stock "under major near-term pressure"
** JP Morgan adds the market will need to wait a long time
before the issues are fully understood, as Medacta will post FY
results only in April 2020
((Linda.pasquini@tr.com))